Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Real World Experience of CAR-T in follicular lymphoma: a Lymphoma Working Party-EBMT study

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Dr. Leyre BENTO & Dr. Silvia MONTOTO

Non-interventional registry-based analysis in the use of Brentuximab Vedotin and/or Checkpoint inhibitors as bridge to autologous stem cell transplantation in Hodgkin lymphoma.

Non-interventional Prospective Studies

Hodgkin’s Disease (HD)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Dr. Ali BAZARBACHI & Dr. Anna SUREDA

Autologous, Allogeneic Stem-Cell Transplantation and CART Cell therapy for Transformed Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) to High Grade NHL (HGNHL)

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Dr. Charalampia KYRIAKOU & Dr. Nour MOUKALLED

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Arnon Nagler

The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Iman Abou Dalle

Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Avichai Shimoni

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Older matched sibling donor versus young haplo-identical donor for elderly patients with acute myeloid leukemia

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Xavier Poiré

Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Juan Montoro

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Ali Bazarbachi

TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Lin Li & Dr. Yishan Ye

The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Dr. Alexandros Spyridonidis